Table 2 Anticipated outcomes for different comparisons between the 21-gene recurrence score testing strategies (interventions) and comparator scenarios (no testing) per 1000 women with hormone receptor-positive, HER2-negative, lymph node-negative invasive breast cancer.

From: Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative

Outcome

Intervention strategy 1a

Comparator scenario 1b

Absolute difference

Intervention strategy 1a

Comparator scenario 2b

Absolute difference

Intervention strategy 2a

Comparator scenario 2b

Absolute difference

Number of Chemotherapy

180

820

−636

180

314

−134

103

314

−211

Invasive disease recurrence

80

78

2

80

79

−1

80

79

−1

Distant recurrence

27

26

1

28

27

0

27

27

0

Local and distant recurrence

39

38

1

39

39

0

39

39

0

Deaths

24

23

1

24

24

0

24

24

0

  1. aAccording to Supplementary Fig. 3a.
  2. bAccording to Supplementary Fig. 3b.
Back to article page